

Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

<https://marketpublishers.com/r/DF2B9BD23B2AEN.html>

Date: March 2022

Pages: 260

Price: US\$ 2,500.00 (Single User License)

ID: DF2B9BD23B2AEN

Abstracts

Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

SUMMARY

Global Markets Direct's latest Pharmaceutical and Healthcare disease pipeline guide Diabetic Macular Edema - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides an overview of the Diabetic Macular Edema (Metabolic Disorders) pipeline landscape.

Diabetic macular edema (DME) occurs when blood vessels in the retina of patients with diabetes begin to leak into the macula, the part of the eye responsible for detailed central vision. Common symptoms of DME are blurry vision, floaters, double vision, and eventually blindness if it goes untreated. Risk factors include age and diabetes.

REPORT HIGHLIGHTS

Global Markets Direct's Pharmaceutical and Healthcare latest pipeline guide Diabetic Macular Edema - Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update, provides comprehensive information on the therapeutics under development for Diabetic Macular Edema (Metabolic Disorders), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Diabetic Macular Edema (Metabolic Disorders) pipeline guide also reviews of key players involved in therapeutic development for Diabetic Macular Edema and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Pre-Registration, Phase III, Phase II, Phase I, IND/CTA Filed, Preclinical, Discovery and Unknown stages are 3, 12, 25, 18, 3, 61, 10 and 2 respectively. Similarly, the Universities portfolio in Preclinical and Discovery stages comprises 2 and 1 molecules, respectively.

Diabetic Macular Edema (Metabolic Disorders) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

SCOPE

The pipeline guide provides a snapshot of the global therapeutic landscape of Diabetic Macular Edema (Metabolic Disorders).

The pipeline guide reviews pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders) by companies and universities/research institutes based on information derived from company and industry-specific sources.

The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.

The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.

The pipeline guide reviews key companies involved in Diabetic Macular Edema (Metabolic Disorders) therapeutics and enlists all their major and minor projects.

The pipeline guide evaluates Diabetic Macular Edema (Metabolic Disorders) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.

The pipeline guide encapsulates all the dormant and discontinued pipeline projects.

The pipeline guide reviews latest news related to pipeline therapeutics for Diabetic Macular Edema (Metabolic Disorders)

REASONS TO BUY

Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.

Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.

Find and recognize significant and varied types of therapeutics under development for Diabetic Macular Edema (Metabolic Disorders).

Classify potential new clients or partners in the target demographic.

Develop tactical initiatives by understanding the focus areas of leading companies.

Plan mergers and acquisitions meritoriously by identifying key players and it's most promising pipeline therapeutics.

Formulate corrective measures for pipeline projects by understanding Diabetic Macular Edema (Metabolic Disorders) pipeline depth and focus of Indication therapeutics.

Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand

business potential and scope.

Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.

Contents

Introduction

Global Markets Direct Report Coverage

Diabetic Macular Edema - Overview

Diabetic Macular Edema - Therapeutics Development

Pipeline Overview

Pipeline by Companies

Pipeline by Universities/Institutes

Products under Development by Companies

Products under Development by Universities/Institutes

Diabetic Macular Edema - Therapeutics Assessment

Assessment by Target

Assessment by Mechanism of Action

Assessment by Route of Administration

Assessment by Molecule Type

Diabetic Macular Edema - Companies Involved in Therapeutics Development

Diabetic Macular Edema - Drug Profiles

Diabetic Macular Edema - Dormant Projects

Diabetic Macular Edema - Discontinued Products

Diabetic Macular Edema - Product Development Milestones

Featured News & Press Releases

Mar 10, 2022: Health Canada approves Samsung Bioepis and Biogen's BYOOVIZ (SB11), LUCENTIS biosimilar (ranibizumab)

Feb 22, 2022: Rezolute announces positive study results for RZ402, an oral PKI being developed for DME

Feb 14, 2022: UNITY Biotechnology announces additional data from phase 1 study of UBX1325 in advanced vascular eye disease

Feb 14, 2022: Oxurion announces new data on THR-149 phase 2 clinical trial ("KALAHARI") in DME at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Feb 11, 2022: Oxurion announces upcoming presentation on THR-149 phase 2 clinical trial ("KALAHARI") at the Angiogenesis, Exudation, and Degeneration 2022 Conference

Feb 11, 2022: Roche announces presentation of new two-year data of Vabysmo at Angiogenesis, Exudation and Degeneration 2022 on 12 February

Feb 03, 2022: Kodiak Sciences completes enrollment in GLEAM and GLIMMER phase 3 clinical trials of KSI-301 in patients with diabetic macular edema

Jan 28, 2022: FDA approves Genentech's Vabysmo, the first bispecific antibody for the

eye, to treat two leading causes of vision loss

Jan 24, 2022: The Lancet publishes studies showing Roche's faricimab improved and maintained vision in two leading causes of vision loss, extending time between treatments up to four months

Jan 18, 2022: Osaikang subsidiary's bio-innovative drug obtaining clinical trial approval notice

Jan 07, 2022: Oxurion provides update on THR-149

Jan 07, 2022: Oxurion provides update on THR-687

Dec 10, 2021: Novartis reports positive data from diabetic macular oedema trial of Beovu

Dec 09, 2021: Novartis announces positive results from year two of the Phase III trial of Beovu in diabetic macular edema

Nov 30, 2021: Isarna Therapeutics announces first patient enrolled in international phase 2a clinical study in ophthalmology indications Wet AMD and DME

Appendix

Methodology

Coverage

Secondary Research

Primary Research

Expert Panel Validation

Contact Us

Disclaimer

List Of Tables

LIST OF TABLES

Number of Products under Development for Diabetic Macular Edema, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Companies, 2022 (Contd..1)

Number of Products under Development by Companies, 2022 (Contd..2)

Number of Products under Development by Companies, 2022 (Contd..3)

Number of Products under Development by Companies, 2022 (Contd..4)

Number of Products under Development by Universities/Institutes, 2022

Products under Development by Companies, 2022

Products under Development by Companies, 2022 (Contd..1)

Products under Development by Companies, 2022 (Contd..2)

Products under Development by Companies, 2022 (Contd..3)

Products under Development by Companies, 2022 (Contd..4)

Products under Development by Companies, 2022 (Contd..5)

Products under Development by Companies, 2022 (Contd..6)

Products under Development by Companies, 2022 (Contd..7)

Products under Development by Universities/Institutes, 2022

Number of Products by Stage and Target, 2022

Number of Products by Stage and Target, 2022 (Contd..1)

Number of Products by Stage and Mechanism of Action, 2022

Number of Products by Stage and Mechanism of Action, 2022 (Contd..1)

Number of Products by Stage and Route of Administration, 2022

Number of Products by Stage and Molecule Type, 2022

Diabetic Macular Edema - Pipeline by 3SBio Inc, 2022

Diabetic Macular Edema - Pipeline by 4D Molecular Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Aadi Bioscience Inc, 2022

Diabetic Macular Edema - Pipeline by Abpro Corp, 2022

Diabetic Macular Edema - Pipeline by Aciont Inc, 2022

Diabetic Macular Edema - Pipeline by Aerie Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Aldeyra Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Allegro Ophthalmics LLC, 2022

Diabetic Macular Edema - Pipeline by Allgenesis Biotherapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by AmMax Bio Inc, 2022

Diabetic Macular Edema - Pipeline by Ampio Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by ANBITION Srl, 2022

Diabetic Macular Edema - Pipeline by Apexian Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Araim Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Ascentage Pharma Group International, 2022

Diabetic Macular Edema - Pipeline by AsclepiX Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Ashvattha Therapeutics LLC, 2022

Diabetic Macular Edema - Pipeline by AskGene Pharma Inc, 2022

Diabetic Macular Edema - Pipeline by Avirmax Inc, 2022

Diabetic Macular Edema - Pipeline by BetaStem Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Bio-Thera Solutions Ltd, 2022

Diabetic Macular Edema - Pipeline by BioCryst Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Cell Care Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Celltrion Inc, 2022

Diabetic Macular Edema - Pipeline by Celon Pharma SA, 2022

Diabetic Macular Edema - Pipeline by Chengdu Kanghong Pharmaceuticals Group Co Ltd, 2022

Diabetic Macular Edema - Pipeline by Chiome Bioscience Inc, 2022

Diabetic Macular Edema - Pipeline by Clearside BioMedical Inc, 2022

Diabetic Macular Edema - Pipeline by Curacle Co Ltd, 2022

Diabetic Macular Edema - Pipeline by Drive Therapeutics LLC, 2022

Diabetic Macular Edema - Pipeline by Elasmogen Ltd, 2022

Diabetic Macular Edema - Pipeline by Eluminex Biosciences Ltd, 2022

Diabetic Macular Edema - Pipeline by Everglades Biopharma LLC, 2022

Diabetic Macular Edema - Pipeline by Exonate Ltd, 2022

Diabetic Macular Edema - Pipeline by EyeGene Inc, 2022

Diabetic Macular Edema - Pipeline by F. Hoffmann-La Roche Ltd, 2022

Diabetic Macular Edema - Pipeline by Gene Signal International SA, 2022

Diabetic Macular Edema - Pipeline by GlaxoSmithKline Plc, 2022

Diabetic Macular Edema - Pipeline by Graybug Vision Inc, 2022

Diabetic Macular Edema - Pipeline by Guangdong Zhongsheng Pharmaceutical Co Ltd, 2022

Diabetic Macular Edema - Pipeline by Huabo Biopharm (Shanghai) Co Ltd, 2022

Diabetic Macular Edema - Pipeline by Huadong Medicine Co Ltd, 2022

Diabetic Macular Edema - Pipeline by Ikarovec Ltd, 2022

Diabetic Macular Edema - Pipeline by Innovent Biologics Inc, 2022

Diabetic Macular Edema - Pipeline by Isarna Therapeutics GmbH, 2022

Diabetic Macular Edema - Pipeline by Johnson & Johnson, 2022

Diabetic Macular Edema - Pipeline by Kala Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Kalos Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Kalvista Pharmaceuticals Inc, 2022

Diabetic Macular Edema - Pipeline by Kanaph Therapeutics Inc, 2022

Diabetic Macular Edema - Pipeline by Kiora Pharmaceuticals Inc, 2022
Diabetic Macular Edema - Pipeline by Kodiak Sciences Inc, 2022
Diabetic Macular Edema - Pipeline by Kowa Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Kubota Vision Inc, 2022
Diabetic Macular Edema - Pipeline by Kuur Therapeutics Ltd, 2022
Diabetic Macular Edema - Pipeline by Laboratorios Sophia SA de CV, 2022
Diabetic Macular Edema - Pipeline by Luye Pharma Group Ltd, 2022
Diabetic Macular Edema - Pipeline by Mabion SA, 2022
Diabetic Macular Edema - Pipeline by Mabwell Shanghai Bioscience Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Molecular Partners AG, 2022
Diabetic Macular Edema - Pipeline by NeuMedics Inc, 2022
Diabetic Macular Edema - Pipeline by Novartis AG, 2022
Diabetic Macular Edema - Pipeline by Novelty Nobility Inc, 2022
Diabetic Macular Edema - Pipeline by Noveome Biotherapeutics Inc, 2022
Diabetic Macular Edema - Pipeline by Oak Hill Bio Inc, 2022
Diabetic Macular Edema - Pipeline by OccuRx Pty Ltd, 2022
Diabetic Macular Edema - Pipeline by Ocugen Inc, 2022
Diabetic Macular Edema - Pipeline by Ocular Therapeutix Inc, 2022
Diabetic Macular Edema - Pipeline by Oculis SA, 2022
Diabetic Macular Edema - Pipeline by OcuNexus Therapeutics Inc, 2022
Diabetic Macular Edema - Pipeline by OcuTerra Therapeutics Inc, 2022
Diabetic Macular Edema - Pipeline by Opthea Ltd, 2022
Diabetic Macular Edema - Pipeline by Outlook Therapeutics Inc, 2022
Diabetic Macular Edema - Pipeline by Oxular Ltd, 2022
Diabetic Macular Edema - Pipeline by Oxurion NV, 2022
Diabetic Macular Edema - Pipeline by PanOptica Inc, 2022
Diabetic Macular Edema - Pipeline by Phanes Therapeutics Inc, 2022
Diabetic Macular Edema - Pipeline by PharmAbcine Inc, 2022
Diabetic Macular Edema - Pipeline by Pleryon Therapeutics Ltd, 2022
Diabetic Macular Edema - Pipeline by Profarma, 2022
Diabetic Macular Edema - Pipeline by Qilu Pharmaceutical Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Rebio Technologies Ltd, 2022
Diabetic Macular Edema - Pipeline by Regeneron Pharmaceuticals Inc, 2022
Diabetic Macular Edema - Pipeline by RemeGen Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Rezolute Inc, 2022
Diabetic Macular Edema - Pipeline by RiniSight Inc, 2022
Diabetic Macular Edema - Pipeline by Ripple therapeutics Corp, 2022
Diabetic Macular Edema - Pipeline by Samsung Bioepis Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Semathera Inc, 2022

Diabetic Macular Edema - Pipeline by Senju Pharmaceutical Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Shanghai SIMR Biotech Co Ltd, 2022
Diabetic Macular Edema - Pipeline by Surrozen Inc, 2022
Diabetic Macular Edema - Pipeline by Suzhou Stainwei Biotech Inc, 2022
Diabetic Macular Edema - Pipeline by Targeted Therapy Technologies LLC, 2022
Diabetic Macular Edema - Pipeline by Theravance Biopharma Inc, 2022
Diabetic Macular Edema - Pipeline by Uni-Bio Science Group Ltd, 2022
Diabetic Macular Edema - Pipeline by Unity Biotechnology Inc, 2022
Diabetic Macular Edema - Pipeline by Verseon Corp, 2022
Diabetic Macular Edema - Pipeline by Xbrane Biopharma AB, 2022
Diabetic Macular Edema - Pipeline by YD Life Science Co, 2022
Diabetic Macular Edema - Pipeline by Zhaoke (Guangzhou) Ophthalmology
Pharmaceutical Ltd, 2022
Diabetic Macular Edema - Dormant Projects, 2022
Diabetic Macular Edema - Dormant Projects, 2022 (Contd..1)
Diabetic Macular Edema - Dormant Projects, 2022 (Contd..2)
Diabetic Macular Edema - Discontinued Products, 2022

List Of Figures

LIST OF FIGURES

Number of Products under Development for Diabetic Macular Edema, 2022

Number of Products under Development by Companies, 2022

Number of Products under Development by Universities/Institutes, 2022

Number of Products by Top 10 Targets, 2022

Number of Products by Stage and Top 10 Targets, 2022

Number of Products by Top 10 Mechanism of Actions, 2022

Number of Products by Stage and Top 10 Mechanism of Actions, 2022

Number of Products by Top 10 Routes of Administration, 2022

Number of Products by Stage and Top 10 Routes of Administration, 2022

Number of Products by Top 10 Molecule Types, 2022

Number of Products by Stage and Top 10 Molecule Types, 2022

I would like to order

Product name: Diabetic Macular Edema Drugs in Development by Stages, Target, MoA, RoA, Molecule Type and Key Players, 2022 Update

Product link: <https://marketpublishers.com/r/DF2B9BD23B2AEN.html>

Price: US\$ 2,500.00 (Single User License / Electronic Delivery)

If you want to order Corporate License or Hard Copy, please, contact our Customer Service:

info@marketpublishers.com

Payment

To pay by Credit Card (Visa, MasterCard, American Express, PayPal), please, click button on product page <https://marketpublishers.com/r/DF2B9BD23B2AEN.html>

To pay by Wire Transfer, please, fill in your contact details in the form below:

First name:
Last name:
Email:
Company:
Address:
City:
Zip code:
Country:
Tel:
Fax:
Your message:

****All fields are required**

Customer signature _____

Please, note that by ordering from marketpublishers.com you are agreeing to our Terms & Conditions at <https://marketpublishers.com/docs/terms.html>

To place an order via fax simply print this form, fill in the information below and fax the completed form to +44 20 7900 3970

